Faes Farma S.A./€FAE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Faes Farma S.A.
Faes Farma S.A. is a pharmaceutical company engaged in the research, production, and marketing of pharmaceutical products. Headquartered in Leioa, Spain, the company operates primarily in the pharmaceuticals and animal health sectors. Key products include prescription medications for human health, over-the-counter medicines, and nutritional supplements, as well as products for veterinary use. Founded in 1933, Faes Farma has expanded its operations to various international markets, particularly in Europe and Latin America. Its competitive strength lies in its robust R&D capabilities and a well-established distribution network.
- Ticker
- €FAE
- Sector
- Health
- Primary listing
- BME
- Employees
- 2,611
- Headquarters
- Leioa, Spain
- Website
- faesfarma.com
Faes Farma S.A. Metrics
BasicAdvanced
€1.6B
19.47
€0.26
0.33
€0.10
2.07%
Price and volume
Market cap
€1.6B
Beta
0.33
52-week high
€5.84
52-week low
€4.34
Average daily volume
170K
Dividend rate
€0.10
Financial strength
Total debt to equity
0.579
Interest coverage (TTM)
8.96%
Profitability
EBITDA (TTM)
124.392
Gross margin (TTM)
65.19%
Net profit margin (TTM)
10.89%
Operating margin (TTM)
12.98%
Effective tax rate (TTM)
6.53%
Revenue per employee (TTM)
€280,000
Management effectiveness
Valuation
Price to earnings (TTM)
19.473
Price to revenue (TTM)
2.118
Price to book
2.01
Price to tangible book (TTM)
5.95
Dividend yield (TTM)
2.07%
Growth
Revenue change (TTM)
28.96%
3-year revenue growth (CAGR)
16.02%
10-year revenue growth (CAGR)
12.55%
3-year dividend per share growth (CAGR)
-17.86%
What the Analysts think about Faes Farma S.A.
Analyst ratings (Buy, Hold, Sell) for Faes Farma S.A. stock.
Analyst projections of the future price of Faes Farma S.A. stock.
Bulls say / Bears say
SIFI and Edol have given Faes Farma a meaningful foothold in ophthalmology: the division contributed €96.8 million, or 17% of group revenue, in the first nine months of 2026. That adds a new growth platform and broadens the product mix. (Faes Farma)
Direct international markets grew 75% in the first nine months, while calcifediol sales rose 19% and animal nutrition and health revenue increased 18%. This growth across markets and business lines gives the group more ways to offset weakness in individual products. (Faes Farma)
Faes Farma reported new progress in its product pipeline, including reimbursement approval for Akantior in Italy alongside Spain and European approval for a higher-strength mesalazine tablet. These milestones could support future growth beyond its established medicines. (StockAnalysis)
Generic competition after bilastine’s Japanese patent expiry is weighing on licensing revenue, which fell 16% in the first nine months. Management expects the Japan impact to continue into 2027, even if it is smaller than in 2026. (Faes Farma, StockAnalysis)
Profit growth is lagging sales growth: nine-month revenue rose 24%, but net profit increased only 1%. Higher amortisation from acquisitions and increased financing costs are weighing on earnings as the enlarged group is integrated. (Faes Farma, StockAnalysis)
Santander maintained a neutral view, arguing that much of the value is already reflected in the share price and highlighting uncertainty over Akantior’s adoption and reimbursement. That leaves less room for upside if the new eye-care product does not gain traction as hoped. (ECOBOLSA)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.
Faes Farma S.A. Financial Performance
Revenues and expenses
Faes Farma S.A. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.